This news release is issued by FUJIFILM Corporation in Japan.
Fujifilm makes no representation that products on this news release are commercially available in all countries and regions（including US and EU). Approved uses of healthcare products vary by country and region.
Specifications and appearance of products are subject to change without notice.
TOKYO, December 17, 2020 ― FUJIFILM Corporation (President: Kenji Sukeno) is pleased to announce that it has filed an application with the Pharmaceuticals and Medical Devices Agency to obtain manufacturing and marketing approval for a rapid and simple antigen test kit for detecting SARS-CoV-2, using silver amplification immunochromatography method 1, as in-vitro diagnostic medical device. This kit has been developed with the use of highly-sensitive detection technology based on silver halide amplification response used in the photo-developing process.